I have experience with both machines.
The Maestro 2 is identical (in software and hardware) to the Maestro 1 except for the addition of a port that can accept a separate OCT-angiography machine. Their OCT-angiography is not FDA approved and they don't even have a timeline of when it will happen (if it even does). It's not worth the added cost at this point.
I believe the Maestro is about $45,000 (again, without angiography). It is serviceable for retina evaluations but NOT in a busy practice with multiple docs. The image acquisition is slow and clunky. If you're a small guy on your own or if you have a small satellite office it may work as a combo photography/OCT station.
The glaucoma portion of the Maestro is weak. Retina it works pretty well (and it's nice to have the OCT linked to the photo - but remember you can't bill for both; you'll lose photo revenue because of this). The RNFL segmentation really isn't trustworthy and the guided progression analysis is dismal. They give you some dots/lines/projections but there is no way to see the actual numbers being analyzed like the Zeiss machine. The other thing that bugs me is the software - viewing reports on the machine and is awkward and there are so many ways to generate a report that your technicians will send images to your EMR in different formats. I almost never see a macula OCT displayed the same way twice in a row with this machine.
The Cirrus 6000 is a thing of beauty. If you get angiography you're looking at an $85,000 price tag. Truth be told, I don't think this machine will give you a clinical advantage compared to the 5000. OCT-Angiography is nice to play with but I haven't seen a clinical study yet that shows superior management of AMD or CNV compared to traditional OCT (my knowledge may be obsolete and our retina-experts here can chime in). I think you could save some cash and stick with the 5000 machine.
One downside to the Zeiss is that they created and are pushing this extra software that is pricey for glaucoma trending. It's called "Glaucoma Workplace" (
ZEISS Ophthalmology Data Management Systems). It's an expensive subscription-based model. As they push more and more for this software I could see the local-machine processing getting weaker in the future.
Just my thoughts.